- Home
- GLPG vs CLM Comparison
GLPG vs CLM Comparison
Compare GLPG & CLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- CLM
- Stock Information
- Founded
- GLPG 1999
- CLM 1987
- Country
- GLPG Belgium
- CLM United States
- Employees
- GLPG N/A
- CLM N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- CLM Finance/Investors Services
- Sector
- GLPG Health Care
- CLM Finance
- Exchange
- GLPG Nasdaq
- CLM Nasdaq
- Market Cap
- GLPG 2.1B
- CLM 2.3B
- IPO Year
- GLPG 2005
- CLM N/A
- Fundamental
- Price
- GLPG $30.42
- CLM $8.13
- Analyst Decision
- GLPG Hold
- CLM
- Analyst Count
- GLPG 4
- CLM 0
- Target Price
- GLPG $31.33
- CLM N/A
- AVG Volume (30 Days)
- GLPG 169.3K
- CLM 1.4M
- Earning Date
- GLPG 11-05-2025
- CLM 01-01-0001
- Dividend Yield
- GLPG N/A
- CLM 18.74%
- EPS Growth
- GLPG N/A
- CLM N/A
- EPS
- GLPG N/A
- CLM N/A
- Revenue
- GLPG $336,643,201.00
- CLM N/A
- Revenue This Year
- GLPG $1.77
- CLM N/A
- Revenue Next Year
- GLPG $0.44
- CLM N/A
- P/E Ratio
- GLPG N/A
- CLM N/A
- Revenue Growth
- GLPG 10.31
- CLM N/A
- 52 Week Low
- GLPG $22.36
- CLM $6.25
- 52 Week High
- GLPG $37.78
- CLM $8.84
- Technical
- Relative Strength Index (RSI)
- GLPG 41.14
- CLM 42.73
- Support Level
- GLPG $30.17
- CLM $8.03
- Resistance Level
- GLPG $33.12
- CLM $8.37
- Average True Range (ATR)
- GLPG 0.75
- CLM 0.09
- MACD
- GLPG -0.04
- CLM -0.02
- Stochastic Oscillator
- GLPG 22.55
- CLM 30.56
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About CLM Cornerstone Strategic Value Fund Inc. New
Cornerstone Strategic Value Fund Inc is a closed-end management investment company. The fund's objective is to seek long-term capital appreciation through investments in equity securities of U.S. and non-U.S. companies. It invests in various sectors, which include financials, information technology, healthcare, consumer discretionary, industrials, utilities, energy, telecommunication services, materials, and other sectors.